Protein formulation
US7060268B2 · kind B2 · utility
123Cited by
99References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2003 |
| Grant date | Jun 13, 2006 |
| Priority date | — |
| Expiry date | Aug 14, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.